Related Experiment Video
Updated: Apr 3, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Role of Endovascular Closure of the Left Atrial Appendage in Stroke Prevention for Atrial Fibrillation
1The Division of Cardiovascular Diseases and Department of Internal Medicine, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN, 55905, USA. kiani.jawad@mayo.edu.
Insights
Percutaneous left atrial appendage occlusion (LAAO) offers a novel stroke prevention strategy for non-valvular atrial fibrillation (AF) patients. This approach targets the left atrial appendage, a primary source of clots, providing an alternative to systemic anticoagulation.
Area of Science:
- Cardiology
- Neurology
- Medical Devices
Background:
- Non-valvular atrial fibrillation (AF) significantly increases stroke risk.
- The left atrial appendage (LAA) is the primary source of thromboemboli in AF patients, accounting for ~90% of strokes.
- Systemic anticoagulation therapy for AF-related stroke prevention carries risks like bleeding and compliance issues.
Purpose of the Study:
- To review percutaneous left atrial appendage occlusion (LAAO) devices and techniques for stroke prevention in non-valvular AF.
- To evaluate the efficacy and safety profile of LAAO compared to systemic anticoagulation.
- To discuss patient populations and long-term outcomes associated with LAAO therapy.
Main Methods:
- Review of percutaneous endovascular closure devices and techniques for the LAA.
- Analysis of clinical data on stroke prevention efficacy and safety.
- Comparative assessment of LAAO versus systemic anticoagulation therapy.
Main Results:
- Percutaneous LAAO has emerged as a significant strategy for stroke and systemic embolism prevention in non-valvular AF.
- LAAO offers a local, site-specific therapy with a distinct safety profile.
- Ongoing studies compare various LAAO approaches and long-term outcomes against anticoagulation.
Conclusions:
- Percutaneous LAAO represents a revolutionary advance in stroke prevention for patients with non-valvular AF.
- LAAO provides a promising alternative for patients who cannot tolerate or adhere to systemic anticoagulation.
- Further research and long-term follow-up will solidify the role of LAAO in AF management.
Abstract:
The pathophysiologic mechanism of thromboembolic stroke in the setting of non-valvular atrial fibrillation (AF) resides in the left atrial appendage (LAA). In this setting, approximately 90 % of all strokes originate from this structure. Percutaneous left atrial appendage occlusion (LAAO) therapy has recently emerged as an important strategy for prevention of stroke and systemic embolism in patients with non-valvular AF. Systemic anticoagulation therapy in this AF population, while effective, is associated with a significant bleeding risk, drug compliance issues, and limited reversal strategies. In this manuscript, we will review the percutaneous devices and techniques that allow endovascular closure of the LAA, including their efficacy in stroke prevention, the safety profile of these local site-specific therapies, comparison of the multiple approaches being studied, the index patient populations involved, and long-term follow-up in comparison with systemic anticoagulation therapy. The percutaneous LAAO approach indeed represents an exciting and revolutionary advance in the field of stroke prevention in AF.
